SUMMARY
The U.S. Food and Drug Administration (FDA) has given two oral COVID-19 antiviral medications Emergency Use Authorization (EUA). These new oral antiviral medications Paxlovid and Molnupiravir will be available for health care providers to treat COVID-19 illness within the District in early January 2022. Only a very small number of treatment courses have been supplied to the District of Columbia by the U.S. Government, requiring that use be limited to those patients at greatest risk of severe illness. This Health Notice provides information on the patients for whom treatment with these antivirals is recommended and how to prescribe these medications.